 5. This is a patient population that follows therapy mostly as directed by their local oncologists. This is frequently less stringently adhered to the recommended guidelines for TKI therapy, with more frequent treatment interruptions, and frequently using suboptimal doses of imatinib i.e., less than 300mg daily. The effect of these treatment interruptions and suboptimal dosing on response and development of resistance is unclear. 